hotspot -WSS

hotspot

author：leisure time 2025-09-29 01:38:54 - browse：85993

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Head of FDA's diagnostics center, who led through Covid, retires

WSS

Why some fertility treatments produce more boy babies

A pediatrician calls for Congress to pass the child tax credit deal

The inclusion problem at the heart of rehabilitation research

Inaction leaves children at risk from dangerous chemotherapy drug

Medicare drug price lawsuits could be good politics for Biden

Medical students need to learn the potent medicine of empathy

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

The high cost of giving birth even with insurance

To bolster infectious disease surveillance, genomics powerhouses team up

Supreme Court strikes down use of affirmative action

Bird flu makes raw milk dangerous to consume, mouse study finds

New air purifier tech could be key to improving indoor air quality

Ozempic cut risk of death in diabetes patients with chronic kidney disease

New air purifier tech could be key to improving indoor air quality

Lawsuit challenges CMS nursing home minimum staffing rule

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bird flu makes raw milk dangerous to consume, mouse study finds

hotspot

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Guardant Health colon cancer test endorsed by FDA advisory panel

FDA endorses new sterilization method for medical devices

CVS is on a mission to consolidate health care. Will it work?

Microsoft launches AI tool for clinical documentation through Epic

New research sheds light on how often breast cancer is overdiagnosed

explore

knowledge

focus

leisure time